Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

Abstract:

:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for over 30 years, with disappointing clinical outcome caused by early-acquired chemoresistance. In this disheartening scenario, novel treatment strategies are being implemented in order to either revert or bypass resistance mechanisms. Areas covered: The general mechanism of action of the standard frontline treatment regimens for SCLC, as well as the known resistance mechanisms to these drugs, is reviewed. Moreover, we focus on the current preclinical and clinical evidence on the potential role of PARP inhibitors and rovalpituzumab tesirine (Rova-T) to tackle chemoresistance in SCLC. Expert opinion: Preliminary evidence supports PARP inhibitors and Rova-T as two promising approaches to either revert or bypass chemoresistance in SCLC, respectively. The identification of potential predictive biomarkers of response to these innovative treatments (SLFN11 and DLL3) has shortened the gap between SCLC and personalized targeted therapy. Further large-scale clinical studies are urgently needed for a better designation of PARP inhibitors and Rova-T in the therapeutic algorithm of SCLC patients.

authors

Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

doi

10.1080/14737140.2019.1624530

subject

Has Abstract

pub_date

2019-06-01 00:00:00

pages

461-471

issue

6

eissn

1473-7140

issn

1744-8328

journal_volume

19

pub_type

杂志文章,评审
  • Emerging application of stereotactic body radiation therapy for gynecologic malignancies.

    abstract::Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.81

    authors: Mayr NA,Huang Z,Sohn JW,Lo SS,Teh BS,Lu JJ,Grecula JC,Kunos C

    更新日期:2011-07-01 00:00:00

  • Determining treatment intensity in elderly patients with multiple myeloma.

    abstract:INTRODUCTION:In the majority of cases, multiple myeloma is a disease occurring in elderly patients. In the last decades, a major improvement in myeloma patients' outcome has been achieved with the introduction of several new drugs. However, this positive outcome was less likely to occur in elderly patients. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1496823

    authors: Salvini M,D'Agostino M,Bonello F,Boccadoro M,Bringhen S

    更新日期:2018-09-01 00:00:00

  • Systemic therapy for recurrent endometrial cancer: a review of North American trials.

    abstract::While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.54

    authors: Dellinger TH,Monk BJ

    更新日期:2009-07-01 00:00:00

  • An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.

    abstract:BACKGROUND:Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database. METHODS:Primary mediastinal sarcomas (1988 - 2013) were assembled from the SE...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2017.1378576

    authors: Abdel-Rahman O

    更新日期:2017-11-01 00:00:00

  • Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.

    abstract::Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1168700

    authors: Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

    更新日期:2016-05-01 00:00:00

  • Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?

    abstract::Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.10.1463

    authors: Lang JE,Hall CS,Singh B,Lucci A

    更新日期:2007-10-01 00:00:00

  • Surgical management of bladder cancer in 2003.

    abstract::Recent advances in molecular and cell biology have led to a greater understanding of the basic biology of bladder cancer. However, despite these advances, surgery remains a key component of modern bladder cancer treatment. Endoscopy is the mainstay of the diagnosis and treatment of superficial bladder cancer. Adjuvant...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.781

    authors: Wade M,Seigne JD

    更新日期:2003-12-01 00:00:00

  • Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.

    abstract::Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.1.75

    authors: Yoon GH,Stein JP,Skinner DG

    更新日期:2005-02-01 00:00:00

  • Therapeutic approaches for refractory germ cell cancer.

    abstract:INTRODUCTION:Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing pla...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1450630

    authors: Oing C,Seidel C,Bokemeyer C

    更新日期:2018-04-01 00:00:00

  • Role of PET/PET-CT in the management of sarcomas.

    abstract::Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly propor...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.8.1241

    authors: Kumar R,Chauhan A,Vellimana AK,Chawla M

    更新日期:2006-08-01 00:00:00

  • Targeting RANKL in breast cancer: bone metastasis and beyond.

    abstract::In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.177

    authors: Azim H,Azim HA Jr

    更新日期:2013-02-01 00:00:00

  • Biological agents in head and neck cancer.

    abstract::Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. Different studies in molecular biology of HNC have been carried out, providing useful results fo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.11.1643

    authors: Bossi P,Locati LD,Licitra L

    更新日期:2007-11-01 00:00:00

  • Role and value of diffusion-weighted MRI in the radiotherapeutic management of head and neck cancer.

    abstract::With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.121

    authors: Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

    更新日期:2010-09-01 00:00:00

  • Improving the accuracy in prognosis for Burkitt lymphoma patients.

    abstract::A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866042

    authors: Castillo JJ,Nadeem O

    更新日期:2014-02-01 00:00:00

  • Promising predictors of checkpoint inhibitor response in NSCLC.

    abstract:INTRODUCTION:The development of immune-checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligand (PD-L1) axis has transformed the treatment paradigm in non-small-cell lung cancer, bringing about unprecedented 5-year survival rates. Despite this dramatic improvement, roughly 70% of patients do not der...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1816173

    authors: Alex F,Alfredo A

    更新日期:2020-11-01 00:00:00

  • Kaposi sarcoma as a model of oncogenesis and cancer treatment.

    abstract::Kaposi sarcoma is the most common cancer among HIV-infected individuals and one of the most common cancers in sub-Saharan Africa. Kaposi sarcoma lesions are highly vascularized, and comprised of spindle-shaped tumor cells. Kaposi sarcoma herpesvirus is etiologically linked to Kaposi sarcoma development and encodes gen...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.2.211

    authors: Hansen A,Boshoff C,Lagos D

    更新日期:2007-02-01 00:00:00

  • miRNA expression profiles associated with diagnosis and prognosis in lung cancer.

    abstract::miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.870037

    authors: Jiang C,Hu X,Alattar M,Zhao H

    更新日期:2014-04-01 00:00:00

  • Pembrolizumab for advanced cervical cancer: safety and efficacy.

    abstract::Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850279

    authors: De Felice F,Giudice E,Bolomini G,Distefano MG,Scambia G,Fagotti A,Marchetti C

    更新日期:2020-11-26 00:00:00

  • Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail.

    abstract::Diffuse brain stem glioma is the most devastating of pediatric malignancies. Virtually all children with this disease die within 1-2 years of diagnosis. After three decades of exhaustive research, the key to controlling this malignancy still eludes us. Attempts to improve survival using radiation, chemotherapy and bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.5.663

    authors: Korones DN

    更新日期:2007-05-01 00:00:00

  • Proteasome inhibitors in the treatment of multiple myeloma.

    abstract::Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.13.9

    authors: McBride A,Ryan PY

    更新日期:2013-03-01 00:00:00

  • Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group.

    abstract::Lung cancer is a global health issue. Compared with other common malignancies, the prognosis is poor as many patients present with advanced disease. The National Lung Screening Trial (NLST) aimed to identify and treat early lung cancers using annual low-dose computed tomography (CT) screening in a high-risk group. Whe...

    journal_title:Expert review of anticancer therapy

    pub_type: 评论,杂志文章

    doi:10.1586/era.11.185

    authors: Duke SL,Eisen T

    更新日期:2011-12-01 00:00:00

  • Advances in the treatment of Waldenström's macroglobulinemia.

    abstract::Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma. It is relatively rare, accounting for approximately 2% of all hematological malignancies. The aim of treatment for patients with Waldenström's macr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.329

    authors: Johnson SA

    更新日期:2006-03-01 00:00:00

  • Cladribine in indolent non-Hodgkin's lymphoma.

    abstract::Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.535

    authors: Sigal DS,Saven A

    更新日期:2008-04-01 00:00:00

  • Can diet prevent nonmelanoma skin cancer progression?

    abstract::Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.801

    authors: Black HS

    更新日期:2005-10-01 00:00:00

  • Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.

    abstract::Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.10.1347

    authors: Vansteenkiste J,Wauters I

    更新日期:2007-10-01 00:00:00

  • Role of intensity-modulated radiation therapy in gastrointestinal cancer.

    abstract::Intensity-modulated radiation therapy (IMRT) represents a powerful advance in the planning and delivery of radiation therapy owing to its ability to deliver highly conformal treatment doses while sparing normal tissues. Dosimetric studies have shown the feasibility and theoretical benefit of treating with IMRT over 3D...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.16

    authors: Bockbrader M,Kim E

    更新日期:2009-05-01 00:00:00

  • Minimally invasive cystectomy approaches in the treatment of bladder cancer.

    abstract::Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.52

    authors: Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

    更新日期:2012-06-01 00:00:00

  • Darbepoetin alfa: potential role in managing anemia in cancer patients.

    abstract::Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.4.377

    authors: Pirker R,Smith R

    更新日期:2002-08-01 00:00:00

  • Controversies over the role of radiation therapy for ductal carcinoma in situ.

    abstract::Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.3.433

    authors: Smith BD,Smith GL,Buchholz TA

    更新日期:2008-03-01 00:00:00

  • Unresolved issues in diffuse large B-cell lymphomas.

    abstract::For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.170

    authors: Murawski N,Zwick C,Pfreundschuh M

    更新日期:2010-03-01 00:00:00